Tag Archives: newspaper

Hot Investor Mandate 1: West Coast-Based Family Office Invests Up to $10M Into Early-Stage Therapeutics, Devices, and Tools Companies

31 May

A family office based in the West Coast invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: VC Firm with Offices in New England Seeks Digital Health Platform Companies Relating to Drug Discovery, Delivery, and Manufacturing

24 May

A venture capital firm with offices in the New England region currently manages four funds, two of which are dedicated to sector specific investments. The first focuses on healthcare and life science investments, while the other is focused on investing in built environment technology. On average, the initial size of investment is up to $1M, and the firm has the capacity to invest $2-4 M after the initial investment. The firm initially invests from Seed to Series A typically, but has come in at later stage investments. The firm is willing to lead in seed rounds and co-invest in later rounds. The firm has a preference for investing in US, but can invest globally. The firm is actively seeking new investment opportunities.

The firm is a flexible investor that is currently looking for life science platforms relating to drug discovery, delivery, and manufacturing and digital health companies. The firm typically does not invest in therapeutics, medical devices, and diagnostics. The firm prefers enterprise to direct-to-consumer health IT companies. In addition, the firm prefers companies that meet at least $1M revenue traction on the health IT side.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: California-Based VC Seeking to Invest in Therapeutic Technologies that Solve Problems Within Genetically Driven Diseases

17 May

A California-based firm backed by a number of well-known global funds is actively seeking investment opportunities. The firm prefers to be the first institutional investor in a company, and is typically an active, lead investor (often the sole investor). The firm typically invests in 5 opportunities per year.

The firm focuses on genetic drivers of disease, and therefore only invests in treatments for monogenic diseases or genetically-driven cancers. The firm is only interested in treatments that elicit a disease-modifying response; treatments that target symptoms of monogenic diseases are not of interest. Therapeutics must have a clearly-defined mechanism of action. The firm usually invests at the preclinical stage, up to 18 months prior to IND, but is open to later stage candidates (including clinical).

The firm focuses on individual products, not technology platforms. The firm typically houses each single asset in its own discrete subsidiary. The firm has internal expertise in medicinal chemistry, biology, and clinical trials, with personnel having significantly contributed to 30+ INDs and 10+ approved drugs. The company will often leverage internal expertise for subsidiaries, and can also assist with recruiting.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Family Office Creates Investment Arm for Medical Device Companies Based in the U.S.

10 May

A family office arm specializes in investing in and operating medical device companies in which it holds a controlling interest. The firm looks to invest in early and seed stage companies with the goal of investing in 1-2 companies per year to add to its portfolio.

The firm looks to invest in medical device companies that are still in development. The firm prefers technologies subject to the FDA 510(k) pathway, but will consider PMA/combination device and therapeutics if the technology is extremely disruptive. The investors are agnostic with regards to subsector and indication. Current portfolio companies include surgical tools for cardiovascular interventions, consumer health electronics, hospital hardware and therapeutic delivery devices for multiple clinical applications.

The firm looks to invest in companies with great technology that need operational expertise to help advance the technology to market with the goal of leveraging its internal management team for execution of product development, regulatory, and commercial strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Venture Firm Seeking Cellular Engineering Technologies for Diagnostics, Devices, and Therapeutics

10 May

A venture fund focusing on the frontiers of the intersection of science and technology looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: